Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Noven Pharmaceuticals, Inc.
This is a multi-center, randomized, double-blind, and placebo-controlled phase 3 study evaluating the safety and efficacy of HP-5000 in subjects with OA pain of the knees. The study will consist of up to a 28-day Screening Phase that will include a Washout Period of current prescription and over the counter (OTC) analgesics; a 12-week Double-blind Treatment Phase, and a 1-week safety Follow-up Phase.
Age
40–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged 40 to 85 years with a clinical diagnosis of OA of the target knee according to the American College of Rheumatology criteria.
Has an X-ray of the target knee, taken no more than 1 year before Baseline, showing evidence of OA.
Has pain of OA in the designated/target study knee.
You may not be if
Body mass index (BMI) \> 40.
Any subject who did not follow the restriction of prohibited therapies during Washout period.
Arthritis of the target knee that is not caused by OA but caused by diseases such as rheumatoid arthritis, gout, psoriasis, syphilitic arthropathy, ochronosis, metabolic or other primary bone disease, or acute traumatic injury.